Illumina, Inc. (NASDAQ:ILMN) Director Robert S. Epstein sold 1,250 shares of the stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $226.55, for a total value of $283,187.50. Following the transaction, the director now directly owns 9,088 shares in the company, valued at approximately $2,058,886.40. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Shares of Illumina, Inc. (NASDAQ ILMN) opened at $213.98 on Thursday. The company has a quick ratio of 3.73, a current ratio of 4.22 and a debt-to-equity ratio of 0.41. Illumina, Inc. has a 52-week low of $119.37 and a 52-week high of $230.72. The company has a market capitalization of $30,814.76, a P/E ratio of 61.71, a price-to-earnings-growth ratio of 3.49 and a beta of 0.79.
Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Tuesday, October 24th. The life sciences company reported $1.11 EPS for the quarter, topping the Zacks’ consensus estimate of $0.99 by $0.12. The company had revenue of $714.00 million during the quarter, compared to the consensus estimate of $692.77 million. Illumina had a return on equity of 19.42% and a net margin of 30.34%. The company’s quarterly revenue was up 17.6% on a year-over-year basis. During the same quarter last year, the company earned $0.97 EPS. sell-side analysts expect that Illumina, Inc. will post 3.75 earnings per share for the current fiscal year.
A number of research analysts have recently commented on the company. Zacks Investment Research raised Illumina from a “hold” rating to a “buy” rating and set a $252.00 price objective on the stock in a report on Tuesday. BidaskClub lowered Illumina from a “buy” rating to a “hold” rating in a report on Wednesday. Wells Fargo & Company reissued a “market perform” rating and set a $205.00 price objective (up previously from $200.00) on shares of Illumina in a report on Wednesday, October 25th. Barclays reissued an “equal weight” rating and set a $150.00 price objective on shares of Illumina in a report on Wednesday, August 9th. Finally, Bank of America increased their price objective on Illumina from $215.00 to $240.00 and gave the company a “buy” rating in a report on Wednesday, October 25th. One analyst has rated the stock with a sell rating, nine have given a hold rating and fourteen have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $201.98.
Institutional investors have recently bought and sold shares of the stock. Dupont Capital Management Corp bought a new position in shares of Illumina during the 3rd quarter worth approximately $153,000. Advisory Services Network LLC lifted its position in shares of Illumina by 13.0% during the 2nd quarter. Advisory Services Network LLC now owns 772 shares of the life sciences company’s stock worth $134,000 after buying an additional 89 shares during the period. Penserra Capital Management LLC lifted its position in shares of Illumina by 13.0% during the 2nd quarter. Penserra Capital Management LLC now owns 884 shares of the life sciences company’s stock worth $153,000 after buying an additional 102 shares during the period. Paradigm Asset Management Co. LLC lifted its position in shares of Illumina by 5.6% during the 2nd quarter. Paradigm Asset Management Co. LLC now owns 950 shares of the life sciences company’s stock worth $165,000 after buying an additional 50 shares during the period. Finally, West Coast Financial LLC bought a new position in shares of Illumina during the 3rd quarter worth approximately $216,000. Institutional investors and hedge funds own 91.75% of the company’s stock.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.